Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review

Executive Summary

Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.

Advertisement

Related Content

J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More
ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Lilly To Rival Pfizer's Ibrance As Early As 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register